Short-course of interferon-β for the treatment of chronic hepatitis C: A multicenter trial for evaluating host immunological parameters

Hidetsugu Saito, H. Ebinuma, M. Takahashi, K. Atsukawa, T. Ohishi, H. Ishii, Y. Kiryu, N. Inagaki, K. Tsukada, Y. Miyamoto, Y. Yonei, T. Morishita, S. Tanaka, S. Miyaguchi, K. Tsuchimoto, N. Kawamura, Y. Oda, K. Suzuki, Shinzo Kato, H. KomatsuM. Yoshioka, A. Shibuya, K. Ishii, K. Kashiwazaki, E. Sekizuka, T. Yoshida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Host immunological parameters have not been evaluated in the response to IFN-β treatment for chronic hepatitis C. In this study, two different treatment regimens of IFN-β for chronic hepatitis C were evaluated and serum hepatitis C virus RNA levels were quantified by multicyclic reverse transcription-polymerase chain reaction. In addition, two host immunological parameters were assayed during treatment. One hundred and fifteen patients with chronic hepatitis C received 6 million units of IFN-β daily for 6 weeks or daily for 2 weeks, followed by twice a week for 14 weeks (total 16 weeks) intravenously. The efficacy of treatment was significantly correlated with initial viral load, which was confirmed by multivariate analysis. No correlation was noted between response to therapy and host immunological parameters. These findings suggest that initial hepatitis C virus levels are one of the important factors in determining the response to IFN-β.

Original languageEnglish
Pages (from-to)115-128
Number of pages14
JournalInternational Journal of Immunotherapy
Volume14
Issue number2
Publication statusPublished - 1998

Fingerprint

Chronic Hepatitis C
Interferons
Multicenter Studies
Hepacivirus
Therapeutics
Viral Load
Reverse Transcription
Multivariate Analysis
RNA
Polymerase Chain Reaction
Serum

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Short-course of interferon-β for the treatment of chronic hepatitis C : A multicenter trial for evaluating host immunological parameters. / Saito, Hidetsugu; Ebinuma, H.; Takahashi, M.; Atsukawa, K.; Ohishi, T.; Ishii, H.; Kiryu, Y.; Inagaki, N.; Tsukada, K.; Miyamoto, Y.; Yonei, Y.; Morishita, T.; Tanaka, S.; Miyaguchi, S.; Tsuchimoto, K.; Kawamura, N.; Oda, Y.; Suzuki, K.; Kato, Shinzo; Komatsu, H.; Yoshioka, M.; Shibuya, A.; Ishii, K.; Kashiwazaki, K.; Sekizuka, E.; Yoshida, T.

In: International Journal of Immunotherapy, Vol. 14, No. 2, 1998, p. 115-128.

Research output: Contribution to journalArticle

Saito, H, Ebinuma, H, Takahashi, M, Atsukawa, K, Ohishi, T, Ishii, H, Kiryu, Y, Inagaki, N, Tsukada, K, Miyamoto, Y, Yonei, Y, Morishita, T, Tanaka, S, Miyaguchi, S, Tsuchimoto, K, Kawamura, N, Oda, Y, Suzuki, K, Kato, S, Komatsu, H, Yoshioka, M, Shibuya, A, Ishii, K, Kashiwazaki, K, Sekizuka, E & Yoshida, T 1998, 'Short-course of interferon-β for the treatment of chronic hepatitis C: A multicenter trial for evaluating host immunological parameters', International Journal of Immunotherapy, vol. 14, no. 2, pp. 115-128.
Saito, Hidetsugu ; Ebinuma, H. ; Takahashi, M. ; Atsukawa, K. ; Ohishi, T. ; Ishii, H. ; Kiryu, Y. ; Inagaki, N. ; Tsukada, K. ; Miyamoto, Y. ; Yonei, Y. ; Morishita, T. ; Tanaka, S. ; Miyaguchi, S. ; Tsuchimoto, K. ; Kawamura, N. ; Oda, Y. ; Suzuki, K. ; Kato, Shinzo ; Komatsu, H. ; Yoshioka, M. ; Shibuya, A. ; Ishii, K. ; Kashiwazaki, K. ; Sekizuka, E. ; Yoshida, T. / Short-course of interferon-β for the treatment of chronic hepatitis C : A multicenter trial for evaluating host immunological parameters. In: International Journal of Immunotherapy. 1998 ; Vol. 14, No. 2. pp. 115-128.
@article{277d38fa246e4f99b45086e2db170053,
title = "Short-course of interferon-β for the treatment of chronic hepatitis C: A multicenter trial for evaluating host immunological parameters",
abstract = "Host immunological parameters have not been evaluated in the response to IFN-β treatment for chronic hepatitis C. In this study, two different treatment regimens of IFN-β for chronic hepatitis C were evaluated and serum hepatitis C virus RNA levels were quantified by multicyclic reverse transcription-polymerase chain reaction. In addition, two host immunological parameters were assayed during treatment. One hundred and fifteen patients with chronic hepatitis C received 6 million units of IFN-β daily for 6 weeks or daily for 2 weeks, followed by twice a week for 14 weeks (total 16 weeks) intravenously. The efficacy of treatment was significantly correlated with initial viral load, which was confirmed by multivariate analysis. No correlation was noted between response to therapy and host immunological parameters. These findings suggest that initial hepatitis C virus levels are one of the important factors in determining the response to IFN-β.",
author = "Hidetsugu Saito and H. Ebinuma and M. Takahashi and K. Atsukawa and T. Ohishi and H. Ishii and Y. Kiryu and N. Inagaki and K. Tsukada and Y. Miyamoto and Y. Yonei and T. Morishita and S. Tanaka and S. Miyaguchi and K. Tsuchimoto and N. Kawamura and Y. Oda and K. Suzuki and Shinzo Kato and H. Komatsu and M. Yoshioka and A. Shibuya and K. Ishii and K. Kashiwazaki and E. Sekizuka and T. Yoshida",
year = "1998",
language = "English",
volume = "14",
pages = "115--128",
journal = "International Journal of Immunotherapy",
issn = "0255-9625",
publisher = "Bioscience Ediprint Inc.",
number = "2",

}

TY - JOUR

T1 - Short-course of interferon-β for the treatment of chronic hepatitis C

T2 - A multicenter trial for evaluating host immunological parameters

AU - Saito, Hidetsugu

AU - Ebinuma, H.

AU - Takahashi, M.

AU - Atsukawa, K.

AU - Ohishi, T.

AU - Ishii, H.

AU - Kiryu, Y.

AU - Inagaki, N.

AU - Tsukada, K.

AU - Miyamoto, Y.

AU - Yonei, Y.

AU - Morishita, T.

AU - Tanaka, S.

AU - Miyaguchi, S.

AU - Tsuchimoto, K.

AU - Kawamura, N.

AU - Oda, Y.

AU - Suzuki, K.

AU - Kato, Shinzo

AU - Komatsu, H.

AU - Yoshioka, M.

AU - Shibuya, A.

AU - Ishii, K.

AU - Kashiwazaki, K.

AU - Sekizuka, E.

AU - Yoshida, T.

PY - 1998

Y1 - 1998

N2 - Host immunological parameters have not been evaluated in the response to IFN-β treatment for chronic hepatitis C. In this study, two different treatment regimens of IFN-β for chronic hepatitis C were evaluated and serum hepatitis C virus RNA levels were quantified by multicyclic reverse transcription-polymerase chain reaction. In addition, two host immunological parameters were assayed during treatment. One hundred and fifteen patients with chronic hepatitis C received 6 million units of IFN-β daily for 6 weeks or daily for 2 weeks, followed by twice a week for 14 weeks (total 16 weeks) intravenously. The efficacy of treatment was significantly correlated with initial viral load, which was confirmed by multivariate analysis. No correlation was noted between response to therapy and host immunological parameters. These findings suggest that initial hepatitis C virus levels are one of the important factors in determining the response to IFN-β.

AB - Host immunological parameters have not been evaluated in the response to IFN-β treatment for chronic hepatitis C. In this study, two different treatment regimens of IFN-β for chronic hepatitis C were evaluated and serum hepatitis C virus RNA levels were quantified by multicyclic reverse transcription-polymerase chain reaction. In addition, two host immunological parameters were assayed during treatment. One hundred and fifteen patients with chronic hepatitis C received 6 million units of IFN-β daily for 6 weeks or daily for 2 weeks, followed by twice a week for 14 weeks (total 16 weeks) intravenously. The efficacy of treatment was significantly correlated with initial viral load, which was confirmed by multivariate analysis. No correlation was noted between response to therapy and host immunological parameters. These findings suggest that initial hepatitis C virus levels are one of the important factors in determining the response to IFN-β.

UR - http://www.scopus.com/inward/record.url?scp=7144227931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144227931&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:7144227931

VL - 14

SP - 115

EP - 128

JO - International Journal of Immunotherapy

JF - International Journal of Immunotherapy

SN - 0255-9625

IS - 2

ER -